Combination thymosin-alpha 1 and interferon-alpha 2b in the treatment of anti-HBe-positive chronic hepatitis B in Turkey.

Saruc M, Yuceyar H, Kucukmetin N, Demir MA, Kandiloglu AR

Hepato-gastroenterology1 May 2002Cited by 19 (Europe PMC)

PMID12063993PepBankPUB-12063993

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone7

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

01HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome
In adults with anti-HBe-positive chronic hepatitis B, a regimen of thymosin alpha‑1 with interferon-alpha gave HBV DNA loss and normal ALT in eighteen of 21 patients at the end of 52 weeks.
In plain wordsIn people with chronic hepatitis B, eighteen of 21 lost the virus and had normal liver enzymes on thymosin alpha‑1 plus interferon.
Peptide
Thymosin alpha-1
Outcome
IncreaseResponse at week 52 (HBV DNA loss and normal ALT)
Study
n = 21
Outcome group
Antiviral activity · Infection
Measurements
Responders
87.7%
week 52
Source sentences
Summary
Eighteen (87.7%) of the 21 patients responded by losing serum HBV DNA and normalizing alanine aminotransferase values at the end of the 52-week treatment period.
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty-one patients were enrolled in the study.
Summary · context
Patients received a 26-week combination course of 1.6 mg thymosin-alpha 1 subcutaneously twice a week and 10 MIU interferon-alpha subcutaneously three times a week, followed by interferon-alpha monotherapy at the same dose for another 26 weeks.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1206399301
02HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome
In adults with anti-HBe-positive chronic hepatitis B, sixteen of 21 patients on thymosin alpha‑1 with interferon-alpha were sustained responders at week 78.
In plain wordsIn people with chronic hepatitis B, sixteen of 21 kept normal liver enzymes and no virus at week 78 on thymosin alpha‑1 plus interferon.
Peptide
Thymosin alpha-1
Outcome
IncreaseSustained response at week 78
Study
n = 21
Outcome group
Antiviral activity · Infection
Measurements
Sustained responders
76.2%
week 78
Source sentences
Summary
Sixteen (76.2%) of these patients became sustained responders, with normal alanine aminotransferase and negative HBV DNA at the end of 78 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty-one patients were enrolled in the study.
Summary · context
Patients received a 26-week combination course of 1.6 mg thymosin-alpha 1 subcutaneously twice a week and 10 MIU interferon-alpha subcutaneously three times a week, followed by interferon-alpha monotherapy at the same dose for another 26 weeks.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1206399302
03HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome
In adults with anti-HBe-positive chronic hepatitis B on thymosin alpha‑1 with interferon-alpha, two patients were non-responders.
In plain wordsIn people with chronic hepatitis B, two did not respond to treatment with thymosin alpha‑1 plus interferon.
Peptide
Thymosin alpha-1
Outcome
Not applicableNon-response
Study
n = 21
Outcome group
Antiviral activity · Infection
Source sentences
Summary
Two patients were non-responders
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty-one patients were enrolled in the study.
Summary · context
Patients received a 26-week combination course of 1.6 mg thymosin-alpha 1 subcutaneously twice a week and 10 MIU interferon-alpha subcutaneously three times a week, followed by interferon-alpha monotherapy at the same dose for another 26 weeks.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1206399303
04HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome
In adults with anti-HBe-positive chronic hepatitis B on thymosin alpha‑1 with interferon-alpha, two patients relapsed.
In plain wordsIn people with chronic hepatitis B, two relapsed after treatment with thymosin alpha‑1 plus interferon.
Peptide
Thymosin alpha-1
Outcome
Not applicableRelapse
Study
n = 21
Outcome group
Antiviral activity · Infection
Source sentences
Summary
two relapsed
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty-one patients were enrolled in the study.
Summary · context
Patients received a 26-week combination course of 1.6 mg thymosin-alpha 1 subcutaneously twice a week and 10 MIU interferon-alpha subcutaneously three times a week, followed by interferon-alpha monotherapy at the same dose for another 26 weeks.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1206399304
05HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome
In adults with anti-HBe-positive chronic hepatitis B on thymosin alpha‑1 with interferon-alpha, one patient had a breakthrough during therapy.
In plain wordsIn people with chronic hepatitis B, one had the virus return during treatment with thymosin alpha‑1 plus interferon.
Peptide
Thymosin alpha-1
Outcome
Not applicableBreakthrough during therapy
Study
n = 21
Outcome group
Antiviral activity · Infection
Source sentences
Summary
one had a breakthrough during therapy.
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty-one patients were enrolled in the study.
Summary · context
Patients received a 26-week combination course of 1.6 mg thymosin-alpha 1 subcutaneously twice a week and 10 MIU interferon-alpha subcutaneously three times a week, followed by interferon-alpha monotherapy at the same dose for another 26 weeks.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1206399305
06HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome
In responders with anti-HBe-positive chronic hepatitis B on thymosin alpha‑1 with interferon-alpha, the Knodell histological activity index improved significantly.
In plain wordsIn people with chronic hepatitis B who responded to thymosin alpha‑1 plus interferon, liver tissue damage scores improved.
Peptide
Thymosin alpha-1
Outcome
DecreaseKnodell histological activity index in responders
Study
n = 21
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
Significant improvements in the Knodell histological activity index were observed in the responders.
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty-one patients were enrolled in the study.
Summary · context
Patients received a 26-week combination course of 1.6 mg thymosin-alpha 1 subcutaneously twice a week and 10 MIU interferon-alpha subcutaneously three times a week, followed by interferon-alpha monotherapy at the same dose for another 26 weeks.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1206399306
07HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialSafety outcome
In adults with anti-HBe-positive chronic hepatitis B, thymosin alpha‑1 with interferon-alpha caused no adverse events other than those seen previously with interferon monotherapy.
In plain wordsIn people with chronic hepatitis B, thymosin alpha‑1 plus interferon caused no side effects beyond those already known for interferon alone.
Peptide
Thymosin alpha-1
Outcome
No significant changeAdverse events
Study
n = 21
Outcome group
Adverse events · Whole body
Source sentences
Summary
No adverse events other than those seen previously with interferon monotherapy were reported.
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty-one patients were enrolled in the study.
Summary · context
Patients received a 26-week combination course of 1.6 mg thymosin-alpha 1 subcutaneously twice a week and 10 MIU interferon-alpha subcutaneously three times a week, followed by interferon-alpha monotherapy at the same dose for another 26 weeks.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1206399307

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
10 Oct 2026, 08:55 UTC
Study results updated
Version 2
9 Oct 2026, 03:03 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:02 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.